Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat1
FARN Share
Trades4
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- TRADING UPDATES: Bezant optimistic after Hope & Gorob estimate
30 Oct 2023 - Faron Pharmaceuticals upbeat on latest data in blood cancer trials
11 Oct 2023 - IN BRIEF: Faron Pharmaceuticals' Bexmarilimab shows 50% remission rate
11 Oct 2023 - Faron Pharmaceuticals names interim chief medical officer
21 Sep 2023 - TRADING UPDATES: Faron appoints Birge Berns as interim medical officer
21 Sep 2023 - UK shareholder meetings calendar - next 7 days
15 Sep 2023 - Evgen Pharma hires interim CFO from Faron, chair to retire this month
5 Sep 2023 - AIM WINNERS & LOSERS: Pelatro plummets on delisting plans
29 Aug 2023
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
TRADING UPDATES: Bezant optimistic after Hope & Gorob estimate
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported...
Faron Pharmaceuticals upbeat on latest data in blood cancer trials
(Sharecast News) - Faron Pharmaceuticals announced encouraging updated data from its ongoing phase one and two 'BEXMAB' study into relapsed or refract...
IN BRIEF: Faron Pharmaceuticals' Bexmarilimab shows 50% remission rate
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Says Bexmarilimab study shows 50% remission rate for patie...
Faron Pharmaceuticals names interim chief medical officer
(Sharecast News) - Cancer immunotherapy-focussed biopharmaceutical firm Faron Pharmaceuticals named Dr Birge Berns as its interim chief medical office...
TRADING UPDATES: Faron appoints Birge Berns as interim medical officer
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Evgen Pharma hires interim CFO from Faron, chair to retire this month
(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of inte...
AIM WINNERS & LOSERS: Pelatro plummets on delisting plans
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
Follow the stocks
